{
    "nct_id": "NCT04402151",
    "official_title": "Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer",
    "inclusion_criteria": "* Male aged 21 years or older.\n* Ability to provide signed informed consent and willingness to comply with protocol requirements.\n* Pathologic confirmation of high-risk adenocarcinoma of the prostate gland as follows: a. Gleason 8-10 or tertiary component 5 disease and/or b. PSA of 20 ng/ml or greater and/or c. Tumor stage of T2c or greater; OR Unfavorable intermediate risk (Gleason 4+3=7, >50% of cores involved, or 2 or more intermediate risk factors which include Gleason 7 disease, PSA 10-20, or T2b disease)\n* Participants must agree to use an acceptable form of birth control and utilize condoms for a period of seven days after each PSMA injection, if engaged in sexual activity.\n* No evidence of metastatic disease, including pelvic lymph nodes.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 21 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* Clinical and/or technical factors that would compromise statistical analysis of the PET and/or MR.\n* Contraindications to PSMA IV administration\n* Contraindications to prostate SBRT (history of transurethral resection of prostate; prostate size greater than 150 cc; AUA score greater than 20; history of prior radiation to the prostate)\n* Other unspecified reasons that, in the opinion of investigators, make the subject unsuitable for enrollment\n* Patients on or intending to take abiraterone will be excluded",
    "miscellaneous_criteria": ""
}